Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237)

Drug Metabolism Letters

Volumn 7, Issue 2, 2013, Pages 96-104

  Yang, Johnny J ^a   Li, Yu ^a   Chakravarty, Arijit ^a   Lu, Chuang ^a   Xia, Cindy Q ^a   Chen, Susan ^a   Pusalkar, Sandeep ^a   Zhang, Mengkun ^a   Ecsedy, Jeffrey ^a   Manfredi, Mark G ^a   Wu, Jing Tao ^a   Shyu, Wen Chyi ^a   Balani, Suresh K ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Alisertib; Efficacious dose prediction; Human PK prediction; MLN8237; Preclinical drug metabolism and PK

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; AURORA A KINASE; AZEPINE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CHIMPANZEE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; EXPERIMENTAL DOG; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MITOSIS INDEX; MOUSE; NONHUMAN; OSMOTIC PUMP; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PREDICTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CACO 2 CELL LINE; COLORECTAL NEOPLASMS; DOG; DOSE CALCULATION; DRUG SCREENING; HALF LIFE TIME; HCT116 CELL LINE; LIVER; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PAN TROGLODYTES; PATHOLOGY; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AURORA KINASE A; AZEPINES; CACO-2 CELLS; COLORECTAL NEOPLASMS; DOGS; DRUG DOSAGE CALCULATIONS; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; HCT116 CELLS; HUMANS; INFUSIONS, SUBCUTANEOUS; LIVER; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; MICE, NUDE; MODELS, ANIMAL; MODELS, BIOLOGICAL; PAN TROGLODYTES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901781028     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312807666131229122359     Document Type: Article

References (26)

1. Marumoto, T.; Honda, S.; Hara, T.; Nitta, M.; Hirota, T.; Kohmura, E.; Saya, H. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem., 2003, 278(51), 51786-51795.
2. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov., 2009, 8, 547-566.
3. Katayama, H.; Sen, S. Aurora kinase inhibitors as anticancer molecules. Biochim. Biophys. Acta, 2010, 1799(10-12), 829-839.
4. Cheung, C.H.; Coumar, M.S.; Chang, J.Y.; Hsieh, H.P. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin. Ther. Pat., 2011, 21(6), 857-884.
5. Manfredi, M.G.; Ecsedy, J.A.; Chakravarty, A.; Silverman, L.; Zhang, M.; Hoar, K.M.; Stroud, S.G.; Chen, W.; Shinde, V.; Huck, J.J.; Wysong, D.R.; Janowick, D.A.; Hyer, M.L.; LeRoy, P.J.; Gershman, R.E.; Silva, M.D.; Germanos, M.S.; Bolen, J.B.; Claiborne, C.F.; Sells, T.B. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res., 2011, 17(24), 7614-7624.
6. Görgün, G.; Calabrese, E.; Hideshima, T.; Ecsedy, J.; Perrone, G.; Mani, M.; Ikeda, H.; Bianchi, G.; Hu, Y.; Cirstea, D.; Santo, L.; Tai, Y.T.; Nahar, S.; Zheng, M.; Bandi, M.; Carrasco, R.D.; Raje, N.; Munshi, N.; Richardson, P.; Anderson, K.C. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood, 2010, 115(25), 5202-5213.
7. Maris, J.M.; Morton, C.L.; Gorlick, R.; Kolb, E.A.; Lock, R.; Carol, H.; Keir, S.T.; Reynolds, C.P.; Kang, M.H; Wu, J.; Smith, M.A.; Houghton, P.J. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer, 2010, 55(1), 26-34.
8. Qi, W.; Cooke, L.S.; Liu, X.; Rimsza, L.; Roe, D.J.; Manziolli, A.; Persky, D.O.; Miller, T.P.; Mahadevan, D. Aurora inhibitor alisertib in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem. Pharmacol., 2011, 81(7), 881-890.
9. Huck, J.J.; Zhang, M.; Hyer, M.L.; Yu, L.; Stringer, B.; Yang, Y.; Ecsedy, J.; Manfredi, M.G. Antitumor activity of the Aurora A inhibitor MLN8237 in combination with docetaxel in xenograft models of breast and prostate cancer. Abstract, AACR Annual Meeting, 2009.
10. Zhang, M.; Huck, J.J.; Hyer, M.L.; Ecsedy, J.; Manfredi, M.G. The Aurora A kinase inhibitor MLN8237 combined with rituximab induces additive/synergistic anti-tumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Abstract, ASCO Annual Meeting, 2009.
11. Zhang, M.; Huck, J.J.; Hyer, M.L.; Kannan, K.; Shyu, W.; Chen, S.; Manfredi, M.G.; Ecsedy, J. The investigational Aurora A kinase inhibitor MLN8237 in combination with vincristine demonstrates robust anti-tumor activity in preclinical B-cell Non-Hodgkin's Lymphoma models. Abstract, ASH Annual Meeting, 2011.
12. Kelly, K.R.; Nawrocki, S.T.; Espitia, C.M.; Zhang, M.; Yang, J.J.; Padmanabhan, S.; Ecsedy, J.; Giles, F.J.; Carew, J.S. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int. J. Cancer, 2012, 131(11), 2693-2703.
13. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther., 1997, 283(1), 46-58.
14. Hosea, N.A.; Collard, W.T.; Cole, S.; Maurer, T.S.; Fang, R.X.; Jones H.; Kakar, S.M.; Nakai, Y.; Smith, B.J.; Webster, R.; Beaumont, K. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol., 2009, 49(5), 513-533.
15. Boxenbaum, H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm., 1982, 10(2), 201-227.
16. Mahmood, I.; Balian, J.D. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci., 1996, 85(4), 411-414.
17. Boxenbaum, H.; DiLea, C. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol., 1995, 35(10), 957-966.
18. Wong, H.; Grossman, S.J.; Bai, S.A.; Diamond, S.; Wright, M.R.; Grace, J.E. Jr.; Qian, M.; He, K.; Yeleswaram, K.; Christ, D.D. The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab. Dispos., 2004, 32(12), 1359-1369.
19. Wong, H.; Grace, J.E. Jr.; Wright, M.R.; Browning, M.R.; Grossman, S.J.; Bai, S.A.; Christ, D.D. Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphine. Xenobiotica, 2006, 36(12), 1178-1190.
20. Lin, J.H.; Chiba, M.; Balani, S.K.; Chen, I.W.; Kwei, G.Y.; Vastag, K.J.; Nishime, J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos., 1996, 24, 1111-1120.
21. Houston, J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 1994, 47(9), 1469-1479.
22. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res., 1993, 10, 1093-1095.
23. Dees, E.C.; Cohen, R.B.; von Mehren, M.; Stinchcombe, T.E.; Liu, H.; Venkatakrishnan, K.; Manfredi, M.; Fingert, H.; Burris, H.A. 3rd.; Infante, Jr. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin. Cancer Res., 2012, 18(17), 4775-4784.
24. Tentler, J.J.; Tan, A.C.; Weekes, C.D.; Jimeno, A.; Leong, S.; Pitts, T.M.; Arcaroli, J.J.; Messersmith, W.A.; Eckhardt, S.G. Patientderived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol., 2012, 9(6), 338-350.
25. Chakravarty, A.; Yu, L.; Huck, J.; Zhang, M.; Burke, K.; Galvin, K.; et al Pharmacodynamic/pharmacokinetic/efficacy relationships of MLN8237, a small molecule inhibitor of Aurora A kinase. Abstract, AACR Annual Meeting, 2008.
26. Cervantes, A.; Elez, E.; Roda, D.; Ecsedy, J.; Macarulla, T.; Venkatakrishnan, K.; Roselló, S.; Andreu, J.; Jung, J.; Sanchis-Garcia, J.M.; Piera, A.; Blasco, I.; Maños, L.; Pérez-Fidalgo, J.A.; Fingert, H.; Baselga, J.; Tabernero, J. Phase I pharmacokinetic/ pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res., 2012, 18(17), 4764-4774.